Availability of the basic drugs for treatment of diabetes such as metformin, sulfonylureas, and insulin is reportedly low, while treatment monitoring is sub-optimal given the low access to fasting glucose testing and glycated hemoglobin (HbA1C) testing. The gene discussed is INS; the disease is diabetes mellitus.